Evidence map›Paper›PMID 41689896›Full record

SynthesisBreast (Edinburgh, Scotland)2026

Association between alcohol consumption and breast cancer incidence and prognosis: A systematic review and meta-analysis.

Luca Arecco, Pedro M Cacilhas, Camila Bobato Lara Gismondi, Marco Bruzzone, Gabriella Gentile, Riccardo Gerosa, Eva Blondeaux, Elisa Agostinetto, Chiara Dauccia, Soraia Lobo-Martins and 9 more

Abstract readSystematic ReviewMeta-Analysis
In one paragraph

Synthesis in Breast (Edinburgh, Scotland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Luca AreccoUniversité Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (H.U.B), Institut Jules Bordet, Bruxelles, Belgium; Department of Internal Medicine and Medical Specialties (DIMI), School of Medicine, University of Genova, Genova, Italy. Electronic address: arecco.luca@hubruxelles.be.
Pedro M CacilhasUniversité Paris-Saclay, UVSQ, Gustave Roussy, Inserm, CESP, F-94800, Villejuif, France.
Camila Bobato Lara GismondiHospital Israelita Albert Einstein, São Paulo, SP, Brazil.
Marco BruzzoneU.O. Epidemiologia Clinica, IRCCS Azienda Ospedaliera Metropolitana, Genova, Italy.
Gabriella GentileUniversité Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (H.U.B), Institut Jules Bordet, Bruxelles, Belgium; Department of Radiological, Oncological and Pathological Sciences, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy.
Riccardo GerosaUniversité Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (H.U.B), Institut Jules Bordet, Bruxelles, Belgium; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
Eva BlondeauxU.O. Epidemiologia Clinica, IRCCS Azienda Ospedaliera Metropolitana, Genova, Italy.
Elisa AgostinettoUniversité Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (H.U.B), Institut Jules Bordet, Bruxelles, Belgium.
Chiara DaucciaUniversité Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (H.U.B), Institut Jules Bordet, Bruxelles, Belgium; Department of Internal Medicine and Medical Therapy, University of Pavia, Pavia, Italy.
Soraia Lobo-MartinsUniversité Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (H.U.B), Institut Jules Bordet, Bruxelles, Belgium.
Rafael GrochotSarah Cannon Research Institute (SCRI), London, UK.
Kamal S SainiAddenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Hatem A AzimCairo Cure Oncology Center, Cairo, Egypt.
Marcio DebiasiBreast Unit, Champalimaud Clinical Centre, Champalimaud Foundation, Lisbon, Portugal.
Alex De CaluwéUniversité Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (H.U.B), Institut Jules Bordet, Bruxelles, Belgium.
Laurence BuisseretUniversité Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (H.U.B), Institut Jules Bordet, Bruxelles, Belgium.
Lucia Del MastroDepartment of Internal Medicine and Medical Specialties (DIMI), School of Medicine, University of Genova, Genova, Italy; Department of Medical Oncology, U.O.C. Clinica di Oncologia Medica, IRCCS Azienda Ospedaliera Metropolitana, Genova, Italy.
Matteo LambertiniDepartment of Internal Medicine and Medical Specialties (DIMI), School of Medicine, University of Genova, Genova, Italy; Department of Medical Oncology, U.O.C. Clinica di Oncologia Medica, IRCCS Azienda Ospedaliera Metropolitana, Genova, Italy.
Evandro de AzambujaUniversité Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (H.U.B), Institut Jules Bordet, Bruxelles, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWhile alcohol consumption appears to influence the incidence of breast cancer (BC), its association with prognosis after a BC diagnosis remains less established. This meta-analysis aimed to explore the association between alcohol consumption on both BC incidence and outcomes.

methodsA systematic literature search was conducted up to May 1st, 2025 (CRD42025593784). Retrospective and prospective studies reporting BC incidence, recurrences, and survival outcomes in women with history of alcohol consumption were included. Analyses according to alcohol intake levels (light, intermediate, heavy consumption) were performed. Main outcomes were BC incidence, BC recurrences, BC-specific survival (BCSS), and overall survival (OS). Pooled relative risk (RR) and hazard ratio (HR) with 95% confidence interval (CI) were calculated.

resultsOut of 5208 screened records, 37 studies including 2,565,920 women were included. Among 17 studies reporting on BC incidence, any alcohol consumption was associated with an increased BC incidence (RR 1.17, 95%CI 1.09-1.26; p < 0.001). BC incidence increased proportionally with higher levels of alcohol consumption: light RR 1.13 (95%CI 1.05-1.23; p = 0.002), intermediate RR 1.28 (95%CI 1.18-1.39; p < 0.001)​, and heavy consumption RR 1.52 (95%CI 1.38-1.67; p < 0.001). Among 20 studies assessing BC outcomes, no associations were found between alcohol consumption and BC recurrences (RR 1.02, 95%CI 0.93-1.11) nor BCSS (HR 0.93, 95%CI 0.87-1.00), while light and intermediate alcohol consumption were associated with slightly improved OS: HR 0.85 (95%CI 0.78-0.92; p < 0.001) and HR 0.84 (95%CI 0.75-0.94; p = 0.002), respectively.

conclusionsAmong over 2.5 million women, alcohol consumption was associated with a dose-dependent increased risk of BC, while alcohol consumption did not appear to worsen prognosis in patients with prior BC diagnosis.

Indexed as

Alcohol DrinkingBreast NeoplasmsFemaleHumansIncidenceNeoplasm Recurrence, LocalPrognosisRisk FactorsAlcoholBreast cancerIncidencePrognosisPublic healthRecurrences

Identifiers

PMID41689896
PMCPMC12925132

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.